Personalized outpatient hypoglycemia treatment
Official title: The Feasibility of Personalized Hypoglycemia Outpatient Treatment for People Living With Type 2 Diabetes Mellitus
Run by Ottawa Hospital Research Institute · NCT07094529 · Data updated 2026-11-12
This test tries whether adults with type 2 diabetes can safely treat mild low blood sugar by choosing how much quick carbohydrate to take and when to recheck their fingerstick.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Ottawa Hospital Research Institute Academic / other |
| Locations | 1 site (Ottawa, Ontario) |
| Status | Recruiting |
| Started | July 21, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | July 30, 2025 |
| Trial ID | NCT07094529 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with type 2 diabetes who have been taking insulin or a sulfonylurea for at least one month and who can give consent and attend an in-person visit are the intended participants.
✕Probably not a fit
People with other types of diabetes, with hypoglycemia unawareness, or who had a low blood sugar event within 24 hours before the visit are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this outpatient feasibility protocol at The Ottawa Hospital, adults with type 2 diabetes on insulin or sulfonylureas undergo supervised induction of mild hypoglycemia (capillary glucose 3.0–3.8 mmol/L) using either recumbent cycling or delayed food after taking their usual glucose-lowering medication. Participants choose one of four carbohydrate treatment doses (8, 16, 20, or 32 grams) and one of four recheck intervals (15, 20, 25, or 30 minutes) to test their preferred approach. Study staff monitor glucose and symptoms during and after the intervention to document glucose recovery and safety. The design is single-center and open-label, with participants able to complete one or both induction methods under nursing supervision.
Why it matters
Potential benefit: If successful, this approach could help personalize simple hypoglycemia treatment guidance so people avoid under- or overtreating mild low blood sugar.
How similar studies have gone: Guidelines and prior studies commonly recommend ~15–20 g of fast-acting carbohydrate and a ~15-minute recheck, but testing selectable carbohydrate doses and recheck timings in a supervised outpatient induction is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Consent provided 2. Age \>= 18 years. 3. Diagnosed as type 2 diabetes mellitus. 4. Type 2 diabetes medications include at least one of the following for at least one month prior to entering the study: sulfonylurea or insulin of any type. Exclusion Criteria: * An individual who meets any of the following criteria will be excluded from participation in this study: 1. Diagnosed as another form of diabetes mellitus. 2. Has a history of hypoglycemia unawareness. 3. Had a hypoglycemia event, defined as capillary blood glucose \< 3.9 mmol/L within 24 hours prior to the study visit booking time.
Where it's running
-
The Ottawa Hospital
Ottawa, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Cathy Sun, MD MSc — Ottawa Hospital Research Institute
- Study coordinator: Cathy Sun, MD MSc
- Email: csun@toh.ca
- Phone: 613-738-8333
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pancreatin Added to Standard Diabetes Therapy
Researchers are testing whether adding pancreatin helps people with type 2 diabetes see better blood sugar control when they already take oral meds or insulin.
-
BGM0504 vs. semaglutide in Chinese adults with obesity-related T2DM
In Chinese adults with type 2 diabetes and obesity who aren’t well controlled by diet and exercise, this trial tests BGM0504 injections once a week for 52 weeks against semaglutide to see which helps more with blood sugar, weight, and safety, including whether diabetes stays in remission after stopping treatment.
-
Health for Hungary: Long-term blood and health data collection to study aging and disease onset
This study tests whether routine blood tests plus advanced molecular analyses can help detect the early stages of non-communicable diseases in adults over 40.
-
GlycoQuest: an AI-powered CGM game for kids with type 1 diabetes and their families
A CGM-linked, AI-adaptive serious game is tested with children 6-17 who have type 1 diabetes and their primary caregivers to see if it helps with glucose control and coping in the first year after diagnosis.
-
Miniature breath sensors to detect hypo- and hyperglycemia in young people with diabetes
A small breath-sensor device will try to see if specific breath compounds can signal low or high blood sugar in youths with diabetes.
-
Real-Time Glucose Monitoring in Newly Diagnosed Type 2 Diabetes
This study tests whether real-time glucose monitoring helps people with newly diagnosed type 2 diabetes manage glucose better than traditional finger-prick testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.